These observations rationalize the use of TLR7 (MEDI-9197, MedImmune/3M) or TLR9 ligands to restore TA-pDC activation in the breast cancer environment and their type-I IFN production preventing TA-Treg expansion (Figure 4). Here, PDC is linked to breast carcinoma.